Impact of adjuvant chemotherapy cycles on prognosis of resectable stomach cancer: A retrospective analysis

Asian Pacific Journal of Cancer Prevention

Volumn 14, Issue 1, 2013, Pages 381-386

  Zhang, Wen Ying ^a   Zhang, Wen Jun ^a   Bai, Yu ^a   Yuan, Hai Hua ^b   Liu, Feng ^b   Gao, Jun ^a   Gong, Yan Fang ^a   Jiang, Bin ^b  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Adjuvant chemotherapy; Gastrectomy; Stomach cancer

Indexed keywords

EID: 84877103589     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2013.14.1.381     Document Type: Article

References (28)

1. Aoyama T, Yoshikawa T, Watanabe T, et al (2011). Survival and prognosticators of gastric cancer that recurs after adjuvant chemotherapy with S-1. Gastric Cancer, 14, 150-4.
2. Bang YJ, Kim YW, Yang HK, et al (2012). Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet, 379, 315-21.
3. Cunningham D, Allum WH, Stenning SP, et al (2006). Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med, 355, 11-20.
4. Cunningham D, Starling N, Rao S, et al (2008). Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med, 358, 36-46.
5. Degiuli M, Calvo F (2006). Survival of early gastric cancer in a specialized European center. Which lymphadenectomy is necessary? World J Surg, 30, 2193-203.
6. De Vita F, Giuliani F, Orditura M, et al (2007). Adjuvant chemotherapy with epirubicin, leucovorin, 5-fluorouracil and etoposide regimen in resected gastric cancer patients: a randomized phase III trial by the Gruppo Oncologico Italia Meridionale (GOIM 9602 Study). Ann Oncol, 18, 1354-8.
7. Di Costanzo F, Gasperoni S, Manzione L, et al (2008). Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRC. J Natl Cancer Inst, 100, 388-98.
8. Dikken JL, Jansen EP, Cats A, et al (2010). Impact of the extent of surgery and postoperative chemoradiotherapy on recurrence patterns in gastric cancer. J Clin Oncol, 28, 2430-6.
9. Jeen YT, Yoon SY, Shin SW, et al (2001). Phase II trial of epirubicin, cisplatin, oral uracil and tegafur, and leucovorin in patients with advanced gastric carcinoma. Cancer, 91, 2288-93.
10. Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90.
11. Kang BW, Kim JG, Chae YS, et al (2011). Pilot study of adjuvant chemotherapy with 3-week combination of S-1 and cisplatin for patients with stage II-IV (M0) gastric cancer. Invest New Drugs, 30, 1671-5.
12. Karacetin D, Incekara O (2004). A randomized trial of 5-fluorouracil, leucovorin, cisplatin and epirubicin (PELF) versus 5-fluorouracil, leucovorin and etoposide (ELF) given as adjuvant chemotherapy to patients with resected advanced gastric adenocarcinomas. J BUON, 9, 263-7.
13. Kim DH, Oh CA, Oh SJ, et al (2012). Validation of seventh edition AJCC gastric cancer staging modifications. J Surg Oncol, 105, 26-30.
14. Kulig J, Kolodziejczyk P, Sierzega M, et al (2010). Adjuvant chemotherapy with etoposide, adriamycin and cisplatin compared with surgery alone in the treatment of gastric cancer: a phase III randomized, multicenter, clinical trial. Oncology, 78, 54-61.
15. Lim L, Michael M, Mann GB, et al (2005). Adjuvant therapy in gastric cancer. J Clin Oncol, 23, 6220-32.
16. Moon YW, Jeung HC, Rha SY, et al (2007). Changing patterns of prognosticators during 15-year follow-up of advanced gastric cancer after radical gastrectomy and adjuvant chemotherapy: a 15-year follow-up study at a single korean institute. Ann Surg Oncol, 14, 2730-7.
17. Neri B, Pantaleo P, Giommoni E, et al (2007). Oxaliplatin, 5-fluorouracil/leucovorin and epirubicin as first-line treatment in advanced gastric carcinoma: a phase II study. Br J Cancer, 96, 1043-6.
18. Oba K (2009). Efficacy of adjuvant chemotherapy using tegafur-based regimen for curatively resected gastric cancer: update of a meta-analysis. Int J Clin Oncol, 14, 85-9.
19. Oh SC (2012). Update of adjuvant chemotherapy for resected gastric cancer. J Gastric Cancer, 12, 3-6.
20. Oken MM, Creech RH, Tormey DC, et al (1982). Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol, 5, 649-55.
21. Okines A, Verheij M, Allum W, et al (2010). Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 21, v50-4.
22. Panzini I, Gianni L, Fattori PP, et al (2002). Adjuvant chemotherapy in gastric cancer: a meta-analysis of randomized trials and a comparison with previous meta-analyses. Tumori, 88, 21-7.
23. Paoletti X, Oba K, Burzykowski T, et al (2010). Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA, 303, 1729-37.
24. Sakuramoto S, Sasako M, Yamaguchi T, et al (2007). Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med, 357, 1810-20.
25. Saletti P, Berthold D, Ghielmini M, et al (2007). Adjuvant chemotherapy (ECF regimen) for patients with gastric adenocarcinoma. Hepatogastroenterology, 54, 969-72.
26. Sasako M, Sakuramoto S, Katai H, et al (2011). Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol, 29, 4387-93.
27. Zhang CX, Huang S, Xu N, et al (2007). Phase II study of epirubicin plus oxaliplatin and infusional 5-fluorouracil as first-line combination therapy in patients with metastatic or advanced gastric cancer. Anticancer Drugs, 18, 581-6.
28. Zhao SL, Fang JY (2008). The role of postoperative adjuvant chemotherapy following curative resection for gastric cancer: a meta-analysis. Cancer Invest, 26, 317-25.